ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,297.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $57.19, for a total transaction of $14,297.50. Following the completion of the sale, the vice president now directly owns 56,488 shares of the company's stock, valued at approximately $3,230,548.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, September 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.82, for a total transaction of $14,205.00.
• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.62, for a total transaction of $14,905.00.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $0.10 during trading hours on Tuesday, reaching $58.60. 164,587 shares of the stock traded hands, compared to its average volume of 213,293. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The company's 50-day moving average price is $59.41 and its two-hundred day moving average price is $62.55. The company has a market cap of $1.23 billion, a P/E ratio of 36.63 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analysts' expectations of $129.09 million. During the same quarter in the previous year, the company earned $1.06 EPS. ANI Pharmaceuticals's revenue for the quarter was up 18.5% on a year-over-year basis. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent research reports. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday. They set an "overweight" rating and a $68.00 price objective for the company. Raymond James boosted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Truist Financial reissued a "hold" rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.00.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Innealta Capital LLC purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $65,000. Ridgewood Investments LLC purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth $106,000. XTX Topco Ltd purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth $218,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.